{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:53:11Z","timestamp":1791571991810,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00213-024-06723-5","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T23:09:15Z","timestamp":1734649755000},"page":"45-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and efficacy of dasotraline for patients with attention deficit\/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including GRADE qualifications"],"prefix":"10.1007","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2195-2353","authenticated-orcid":false,"given":"Mohamed Ezzat M.","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Radwan","family":"Alsaadany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Awad E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ezzat","family":"Elmetwalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"11","key":"6723_CR1","first-page":"e49144","volume":"15","author":"B Sapkale","year":"2023","unstructured":"Sapkale B, Sawal A (2023) Attention deficit hyperactivity disorder (ADHD) causes and diagnosis in adults: a review. Cureus 15(11):e49144","journal-title":"Cureus"},{"issue":"1","key":"6723_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s12888-023-04980-w","volume":"23","author":"JH Vold","year":"2023","unstructured":"Vold JH, Halm\u00f8y A, Chalabianloo F, Pierron MC, L\u00f8berg E-M, Johansson KA et al (2023) Attention-deficit\/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study. BMC Psychiatry 23(1):479","journal-title":"BMC Psychiatry"},{"key":"6723_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3389\/fpsyt.2019.00673","volume":"10","author":"V Scandurra","year":"2019","unstructured":"Scandurra V, Emberti Gialloreti L, Barbanera F, Scordo MR, Pierini A, Canitano R (2019) Neurodevelopmental disorders and adaptive functions: a study of children with autism spectrum disorders (ASD) and\/or attention deficit and hyperactivity disorder (ADHD). Front Psychiatry 10:673","journal-title":"Front Psychiatry"},{"issue":"5","key":"6723_CR4","first-page":"467","volume":"119","author":"E Abdelnour","year":"2022","unstructured":"Abdelnour E, Jansen MO, Gold JA (2022) ADHD diagnostic trends: increased recognition or overdiagnosis? Mo Med 119(5):467\u2013473","journal-title":"Mo Med"},{"issue":"10","key":"6723_CR5","doi-asserted-by":"publisher","first-page":"e2336872","DOI":"10.1001\/jamanetworkopen.2023.36872","volume":"6","author":"Y Li","year":"2023","unstructured":"Li Y, Yan X, Li Q, Li Q, Xu G, Lu J et al (2023) Prevalence and trends in diagnosed ADHD among US children and adolescents, 2017\u20132022. JAMA Netw Open 6(10):e2336872","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6723_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13696998.2022.2032097","volume":"25","author":"J Schein","year":"2022","unstructured":"Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M et al (2022) Economic burden of attention-deficit\/hyperactivity disorder among children and adolescents in the United States: a societal perspective. J Med Econ 25(1):193\u2013205","journal-title":"J Med Econ"},{"issue":"2","key":"6723_CR7","first-page":"168","volume":"28","author":"J Schein","year":"2022","unstructured":"Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F et al (2022) Economic burden of attention-deficit\/hyperactivity disorder among adults in the United States: a societal perspective. J Manag Care Spec Pharm 28(2):168\u2013179","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"6723_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5498\/wjp.v7.i1.44","volume":"7","author":"J Balazs","year":"2017","unstructured":"Balazs J, Kereszteny A (2017) Attention-deficit\/hyperactivity disorder and suicide: a systematic review. World J Psychiatry 7(1):44\u201359","journal-title":"World J Psychiatry"},{"issue":"7","key":"6723_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/10870547231158572","volume":"27","author":"AR Kosheleff","year":"2023","unstructured":"Kosheleff AR, Mason O, Jain R, Koch J, Rubin J (2023) Functional impairments associated with ADHD in adulthood and the impact of pharmacological treatment. J Atten Disord 27(7):669\u2013697","journal-title":"J Atten Disord"},{"key":"6723_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-244X-13-59","volume":"13","author":"M Adamou","year":"2013","unstructured":"Adamou M, Arif M, Asherson P, Aw T-C, Bolea B, Coghill D et al (2013) Occupational issues of adults with ADHD. BMC Psychiatry 13:59","journal-title":"BMC Psychiatry"},{"issue":"2","key":"6723_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1060028013510699","volume":"48","author":"A Sharma","year":"2014","unstructured":"Sharma A, Couture J (2014) A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 48(2):209\u2013225","journal-title":"Ann Pharmacother"},{"key":"6723_CR12","doi-asserted-by":"publisher","first-page":"104706","DOI":"10.1016\/j.neuint.2020.104706","volume":"135","author":"E Saboory","year":"2020","unstructured":"Saboory E, Ghasemi M, Mehranfard N (2020) Norepinephrine, neurodevelopment and behavior. Neurochem Int 135:104706","journal-title":"Neurochem Int"},{"issue":"1","key":"6723_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-018-0632-3","volume":"39","author":"MO Klein","year":"2019","unstructured":"Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG (2019) Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol 39(1):31\u201359","journal-title":"Cell Mol Neurobiol"},{"key":"6723_CR14","unstructured":"Functional Roles of Norepinephrine and Dopamine in ADHD [Internet]. [cited 2024 Apr 9]. https:\/\/www.medscape.org\/viewarticle\/523887"},{"key":"6723_CR15","doi-asserted-by":"crossref","unstructured":"Curatolo P, D\u2019Agati E, Moavero R. The neurobiological basis of ADHD. Italian Journal of Pediatrics [Internet]. 2010;36(1):79. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3016271\/ \u200c","DOI":"10.1186\/1824-7288-36-79"},{"issue":"3","key":"6723_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/00004583-199603000-00006","volume":"35","author":"SR Pliszka","year":"1996","unstructured":"Pliszka SR, McCracken JT, Maas JW (1996) Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35(3):264\u2013272","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"6723_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neubiorev.2018.02.001","volume":"87","author":"SV Faraone","year":"2018","unstructured":"Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit\/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255\u2013270","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"6723_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1358\/dot.2013.49.10.2008996","volume":"49","author":"DS Reddy","year":"2013","unstructured":"Reddy DS (2013) Current pharmacotherapy of attention deficit hyperactivity disorder. Drugs Today 49(10):647\u2013665","journal-title":"Drugs Today"},{"key":"6723_CR19","unstructured":"Verghese C, Abdijadid S (2023) Methylphenidate [Internet]. Nih.gov. StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482451\/ \u200c"},{"key":"6723_CR20","unstructured":"Martin D, Le JK (2023) Amphetamine [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556103\/ \u200c"},{"issue":"7","key":"6723_CR21","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.2967\/jnumed.110.084525","volume":"52","author":"C DeLorenzo","year":"2011","unstructured":"DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L et al (2011) SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med 52(7):1150\u20131155","journal-title":"J Nucl Med"},{"key":"6723_CR22","doi-asserted-by":"publisher","first-page":"113359","DOI":"10.1016\/j.biopha.2022.113359","volume":"153","author":"R Schreiber","year":"2022","unstructured":"Schreiber R, Campbell U, Quinton MS, Hardy LW, Fang QK, Lew R (2022) In vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo. Biomed Pharmacother 153:113359","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"6723_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40261-015-0358-7","volume":"36","author":"SC Hopkins","year":"2016","unstructured":"Hopkins SC, Sunkaraneni S, Skende E, Hing J, Passarell JA, Loebel A et al (2016) Pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit\/hyperactivity disorder in adults. Clin Drug Investig 36(2):137\u2013146","journal-title":"Clin Drug Investig"},{"issue":"1","key":"6723_CR24","doi-asserted-by":"publisher","first-page":"e00281","DOI":"10.1002\/prp2.281","volume":"5","author":"Y-L Chen","year":"2017","unstructured":"Chen Y-L, Skende E, Lin J, Yi Y, Wang PL, Wills S et al (2017) Absorption, distribution, metabolism, and excretion of [14\u00a0C]-dasotraline in humans. Pharmacol Res Perspect 5(1):e00281","journal-title":"Pharmacol Res Perspect"},{"issue":"10","key":"6723_CR25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1177\/10870547211073477","volume":"26","author":"S Wigal","year":"2022","unstructured":"Wigal S, Tsai J, Bates JA, Sarma K, Tortorich D, Zhu H et al (2022) A randomized, placebo-controlled laboratory classroom study of the efficacy and safety of dasotraline in children with ADHD. J Atten Disord 26(10):1357\u20131368","journal-title":"J Atten Disord"},{"issue":"2","key":"6723_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/cap.2018.0083","volume":"29","author":"RL Findling","year":"2019","unstructured":"Findling RL, Adler LA, Spencer TJ, Goldman R, Hopkins SC, Koblan KS et al (2019) Dasotraline in children with attention-deficit\/Hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol 29(2):80\u201389","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"6723_CR27","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/npp.2015.124","volume":"40","author":"KS Koblan","year":"2015","unstructured":"Koblan KS, Hopkins SC, Sarma K, Jin F, Goldman R, Kollins SH et al (2015) Dasotraline for the treatment of attention-deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology 40(12):2745\u20132752","journal-title":"Neuropsychopharmacology"},{"key":"6723_CR28","doi-asserted-by":"crossref","unstructured":"McElroy SL, Hudson JI, Grilo CM, Guerdjikova AI, Deng L, Koblan KS et al (2020) Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. J Clin Psychiatry 81(5)","DOI":"10.4088\/JCP.19m13068"},{"issue":"4","key":"6723_CR29","doi-asserted-by":"publisher","first-page":"e0215506","DOI":"10.1371\/journal.pone.0215506","volume":"14","author":"R Halevy-Yosef","year":"2019","unstructured":"Halevy-Yosef R, Bachar E, Shalev L, Pollak Y, Enoch-Levy A, Gur E et al (2019) The complexity of the interaction between binge-eating and attention. PLoS ONE 14(4):e0215506","journal-title":"PLoS ONE"},{"key":"6723_CR30","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"M Page","year":"2021","unstructured":"Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"6723_CR31","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training [Internet]. [cited 2024 Apr 10]. https:\/\/training.cochrane.org\/handbook\/current"},{"key":"6723_CR32","unstructured":"Rayyan \u2013 Intelligent Systematic Review - Rayyan [Internet]. [cited 2024 Apr 10]. https:\/\/www.rayyan.ai\/"},{"key":"6723_CR33","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"Suppl 1","key":"6723_CR34","doi-asserted-by":"publisher","first-page":"I46","DOI":"10.1007\/s00787-006-1007-8","volume":"15","author":"M D\u00f6pfner","year":"2006","unstructured":"D\u00f6pfner M, Steinhausen H-C, Coghill D, Dalsgaard S, Poole L, Ralston SJ et al (2006) Cross-cultural reliability and validity of ADHD assessed by the ADHD rating scale in a pan-european study. Eur Child Adolesc Psychiatry 15(Suppl 1):I46\u201355","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"7","key":"6723_CR35","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4(7):28\u201337","journal-title":"Psychiatry (Edgmont)"},{"issue":"1","key":"6723_CR36","first-page":"47","volume":"34","author":"SB Wigal","year":"1998","unstructured":"Wigal SB, Gupta S, Guinta D, Swanson JM (1998) Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 34(1):47\u201353","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"6723_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/1073191108326924","volume":"16","author":"DW Murray","year":"2009","unstructured":"Murray DW, Bussing R, Fernandez M, Wei Hou, Garvan CW, Swanson JM et al (2009) Psychometric properties of teacher SKAMP ratings from a community sample. Assessment 16(2):193\u2013208","journal-title":"Assessment"},{"issue":"2","key":"6723_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/cap.2010.0047","volume":"21","author":"SB Wigal","year":"2011","unstructured":"Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB et al (2011) Academic, behavioral, and cognitive effects of OROS\u00ae methylphenidate on older children with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol 21(2):121\u2013131","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7521","key":"6723_CR39","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/bmj.331.7521.903","volume":"331","author":"DG Altman","year":"2005","unstructured":"Altman DG, Bland JM (2005) Standard deviations and standard errors. BMJ 331(7521):903","journal-title":"BMJ"},{"issue":"7109","key":"6723_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"key":"6723_CR41","unstructured":"GRADE handbook [Internet] [cited 2024 Apr 10]. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"issue":"2","key":"6723_CR42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1087054719864644","volume":"24","author":"SB Wigal","year":"2020","unstructured":"Wigal SB, Hopkins SC, Koblan KS, Childress A, Kent JM, Tsai J et al (2020) Efficacy and safety of dasotraline in children with ADHD: a laboratory classroom study. J Atten Disord 24(2):192\u2013204","journal-title":"J Atten Disord"},{"issue":"3","key":"6723_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/YIC.0000000000000333","volume":"36","author":"LA Adler","year":"2021","unstructured":"Adler LA, Goldman R, Hopkins SC, Koblan KS, Kent J, Hsu J et al (2021) Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. Int Clin Psychopharmacol 36(3):117\u2013125","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"6723_CR44","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00787-016-0841-6","volume":"25","author":"T Peasgood","year":"2016","unstructured":"Peasgood T, Bhardwaj A, Biggs K, Brazier JE, Coghill D, Cooper CL et al (2016) The impact of ADHD on the health and well-being of ADHD children and their siblings. Eur Child Adolesc Psychiatry 25(11):1217\u20131231","journal-title":"Eur Child Adolesc Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06723-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06723-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06723-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T17:44:52Z","timestamp":1737222292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06723-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6723"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06723-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there exists no competing financial interest or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interest"}}]}}